2343

## Practical & Translational Assessment

### Technical Feasibility: Significant Challenges

**Cell-Type Specificity Problem**: Transcranial focused ultrasound cannot selectively target SST interneurons versus pyramidal neurons in EC layer II within a ~1mm² target zone. Optogenetics achieves this in rodents but requires genetic manipulation—non-translatable to humans. Chemogenetics (DREADDs) similarly require viral delivery. tFUS modulates all neurons in the beam path indiscriminately.

**Spatial Resolution**: Even with advanced phased-array tFUS (sub-mm beam steering), the entorhinal cortex lies ~35mm from the surface. Acoustic diffraction and scatter through the temporal bone make layer-specific targeting (EC-II) extremely questionable with current technology.

**Closed-Loop Requirements**: Real-time gamma detection requires either implanted electrodes (ECoG strip along hippocampus) or MEG/EEG with adequate temporal resolution. The latency between gamma detection and ultrasound delivery must be <10-20ms to be physiologically meaningful—this integration is non-trivial.

### Competitive Landscape

- **Cognito Therapeutics** (Light therapy, 40Hz gamma entrainment) ran NCT04079877 showing slow cognitive decline reduction. Failed Phase II (2024).
- **NeuroEM** (transcranial electromagnetic treatment) completed NCT04458056; results neutral.
- **Healable AI** (audiovisual gamma stimulation) in early trials.
- **INSIGHTEC**, **BrainSonix** pursuing tFUS for epilepsy/tremor.

No company is pursuing subtype-specific interneuron tFUS—this is purely academic theory.

### Safety Concerns

- Chronic tFUS at intensities >3 W/cm² causes microhemorrhage and thermal necrosis in primates (PMID: 30240536)
- Repeated EC targeting raises seizure risk
- Implanted gamma-recording electrodes carry infection/hemorrhage risk (NCT03539246)

### Verdict: Premature

The mechanistic chain (SST → perforant path gating → gamma restoration) is biologically plausible but operationally speculative. Current technology cannot deliver the required specificity. A more feasible near-term step would be: (1) validate 40Hz tFUS hippocampal entrainment in MCI patients (NCT06035929), (2) demonstrate layer-specific targeting in non-human primates, (3) then pursue cell-type specificity via chemogenetic approaches in larger animal models. Timeline: 10-15 years minimum to clinical translation.